Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

December 31, 2007
Erbitux in first line therapy for lung cancer: The result is as thrilling as kissing your sister....
By a GLG Expert Contributor
Analysis of: Randomized Phase II Study of Gemcitabine Plus Cisplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer (jco.ascopubs.org)
"Nothing ventured, nothing gained." The patients were not treated uniformly thus the results are completely inconclusive.
December 28, 2007
Avastin in metastatic breast cancer? I told you so.
By a GLG Expert Contributor
Analysis of: Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer (content.nejm.org)
Avastin + chemo in metastatic breast cancer improves progression but not overall survival. No wonder the FDA rejected it in breast cancer BUT...
December 27, 2007
Revlimid in non 5Q- MDS. It's time is coming!!!!
By a GLG Expert Contributor
Analysis of: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion (bloodjournal.hematologylibrary.org)
Revlimid appears to deliver rather impressive results Re: transfusion independence (or decreased frequency) in Low and intermediate 1 risk non 5Q- MDS.
December 26, 2007
ASH says it and that is the final word on Epo use? (Maybe)
By a GLG Expert Contributor
Analysis of: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline updat (bloodjournal.hematologylibrary.org)
Yada Yada Yada Hemoglobins need to be < 10 grams in order to give Epo.
December 21, 2007
Avastin approved in kidney cancer (RCC) in Europe! Good for Roche but for the patients......
By a GLG Expert Contributor
Analysis of: Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer (www.pipelinereview.com)
Roche received approval for Avastin plus interferon (IFN) in advanced RCC
December 21, 2007
IPI-504: another targeting agent for another target.
By a GLG Expert Contributor
Analysis of: Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer (www.pipelinereview.com)
A phase I/II trial of a heat shock protein 90 (Hsp90) inhibitor is being tested in patients with and without an Epidermal Growth Factor Receptor (EGFR) mutation that "sensitizes" the lung cancer cells to some targeting agents.
December 20, 2007
Ablynx may have a benign antibody for 2 "malignant" conditions
By a GLG Expert Contributor
Analysis of: Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081 (www.pipelinereview.com)
A novel antibody, ALX-0081, that is well tolerated nd is directed against von Willebrand Factor (anti-vWF), that is strongly implicated in taking part in acute coronary events and conclusively responsible for the disastrous outcomes of thrombotic thrombocytopenic purpura (TTP).
December 19, 2007
Reduction in Medicare Payments to Docs?? Don't bet on it.
By a GLG Expert Contributor
Analysis of: Planned Medicare Cuts Weigh on Primary Care (online.wsj.com)
Starting January 1st Medicare will reduce payments to doctors by 10.1% and some physicians may revolt by not seeing Medicare patients.
December 18, 2007
Pfizer's Loss is Wyeth, Novartis and Bayer's Gain
By a GLG Expert Contributor
Analysis of: Targeted cancer drug poses heart risk (www.philly.com)
In one study 11% of an admittedly small group of patients developed cardiac problems.
December 17, 2007
Unwilling to face reality, families will combine potentially toxic agents to treat cancer.
By a GLG Expert Contributor
Analysis of: Lab Rat? (online.wsj.com)
Families will treat their loved ones with combinations of drugs rather than than seeking appropriate clinical trials.

Previous Page : 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Next201 to 210 of 457

Analytics


Generated at 2009-01-07T19:00:58.307